Study identifier:NIS-NKR-SER-2009/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A non-interventional study evaluating the Clinical Benefit and Effectiveness of Quetiapine Fumarate Extended-Release Tablets (SEROQUEL XRâ) in Subjects with Schizophrenia-An observational, multicentric prospective study
schizophrenia
-
No
-
All
1494
Observational
18 Years - 65 Years
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The primary objective of this NIS is to assess the clinical benefit subjects derive from taking seroquel XR, using the CGI-CB. The secondary objective is to assess the effectiveness,safety and tolerability of seroquel XR tablets.
Location
Location
Busan, Republic of Korea
Location
Seoul, Republic of Korea
Location
Daegu, Republic of Korea
Location
Jeju, Republic of Korea
Location
Goyang, Republic of Korea
Location
Kyung gi, Republic of Korea
Location
Kyungju, Republic of Korea
Location
Namyangju, Republic of Korea
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.